CorMedix (NASDAQ:CRMD) and GSK (NYSE:GSK) Head to Head Review

GSK (NYSE:GSK) and CorMedix (NASDAQ:CRMD) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Risk and Volatility

GSK has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for GSK and CorMedix, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2	7	1	1	2.09
CorMedix	0	2	7	0	2.78

GSK presently has a consensus price target of $56.50, suggesting a potential upside of 19.82%. CorMedix has a consensus price target of $15.00, suggesting a potential upside of 102.02%. Given CorMedix’s stronger consensus rating and higher possible upside, analysts clearly believe CorMedix is more favorable than GSK.

Profitability

This table compares GSK and CorMedix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
CorMedix	40.49%	40.52%	20.61%

Institutional & Insider Ownership

15.7% of GSK shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares GSK and CorMedix”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07 billion	2.21	$7.54 billion	$3.20	14.74
CorMedix	$311.71 million	1.86	$163.05 million	$2.14	3.47

GSK has higher revenue and earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Summary

GSK beats CorMedix on 8 of the 15 factors compared between the two stocks.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

About CorMedix

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.